# First Safety Study in Humans of a Single Dose of CPG 52364

> **NCT00547014** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 61 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Placebo Comparator: Cohort 1 Placebo
- **DRUG:** 52364 3 mg
- **DRUG:** Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
- **DRUG:** 52364 10 mg
- **DRUG:** 52364 30 mg
- **DRUG:** 52364 100 mg
- **DRUG:** 52364 1 mg

## Key facts

- **NCT ID:** NCT00547014
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** —
- **Final completion:** 2008-04
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2009-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00547014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00547014, "First Safety Study in Humans of a Single Dose of CPG 52364". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00547014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*